All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FES/FDG Imaging Augments the Metastatic Breast Cancer Diagnostic and Treatment Landscape

September 13th 2023

Sophia Rose O’Brien, MD, discusses the optimal uses for FDG PET/CT and FES PET/CT in patients with metastatic breast cancer; limitations of these imaging modalities to consider, particularly in patients with estrogen receptor-positive disease; and the potential advantages of using FDG assessment in patients with oligometastatic disease.

Maddocks Shares Updates on Emerging Treatment Strategies in MCL

September 12th 2023

Efforts to widen the treatment armamentarium for patients with mantle cell lymphoma have been thwarted by increased toxicities and resistance mechanisms with effective therapies such as BTK inhibitors.

Real-World Analysis Highlights US Treatment Patterns for Frontline Atezolizumab/Bevacizumab in HCC

September 12th 2023

Real-world data from a systemic review of treatment patterns in the United States showed that the majority of patients with hepatocellular carcinoma administered atezolizumab and bevacizumab in the frontline setting discontinued treatment within 12 months, indicating the need for additional research on the effectiveness of this regimen for patients with high-risk disease.

Data for Second-Line or Later Ramucirumab Show Consistent Benefit in Advanced HCC

September 12th 2023

Treatment with ramucirumab in the second line after first-line lenvatinib monotherapy or the combination of atezolizumab and bevacizumab, or as third-line treatment following both regimens, elicited efficacy comparable with second-line ramucirumab following treatment with sorafenib in patients with advanced hepatocellular carcinoma.

JAK Inhibitors Continue to Shape the Treatment Landscape of Myelofibrosis

September 12th 2023

Following the FDA approvals of the JAK inhibitors ruxolitinib, fedratinib, and pacritinib, the treatment landscape of myelofibrosis continues to grow with the use of these agents with an additional FDA review planned for momelotinib in September 2023.

European Approval Sought for Erdafitinib in Locally Advanced or Metastatic FGFR3+ Urothelial Carcinoma

September 12th 2023

A marketing authorization application has been submitted to the European Medicines Agency seeking the approval of erdafitinib for the treatment of adult patients with locally advanced, unresectable or metastatic urothelial carcinoma harboring susceptible FGFR3 alterations who experienced disease progression during or following at least 1 line of therapy containing a PD-1/PD-L1 inhibitor.

FDA Grants Fast Track Designation to AFM13 Plus AlloNK for Relapsed/Refractory Hodgkin Lymphoma

September 12th 2023

The FDA has granted fast track designation to the first-in-class innate cell engager AFM13 plus AlloNK for the treatment of patients with relapsed/refractory Hodgkin lymphoma.

American Oncology Network Celebrates Momentous Five-Year Anniversary of Closing the Cancer Care Gap

September 12th 2023

American Oncology Network, one of the fastest-growing community oncology networks in the United States, proudly celebrated its fifth anniversary, commemorating a half-decade of excellence in advancing community oncology and driving value-based care initiatives to close the cancer care gap.

Rapidly Expanding Treatment Armamentarium Improves Outcomes and Instills Hope in Patients With GI Cancers

September 12th 2023

Daneng Li, MD, highlights the importance of biomarker testing in gastroesophageal and biliary tract cancers, the potential role for targeted therapy in first-line CRC treatment, and when to choose neoadjuvant therapy over upfront surgery and adjuvant therapy in pancreatic cancer.

Randall Spotlights Surgical and Non-Surgical Advances in Musculoskeletal Oncology

September 12th 2023

R. Lor Randall, MD, FACS, discusses the process of organizing the symposium, key surgical and non-surgical advancements as well as socioeconomic disparities identified in these papers, and the importance of this information for both surgical and medical oncologists.

IMpower151 Misses Primary PFS End Point With Frontline Atezolizumab Plus Bevacizumab/Chemo in NSCLC

September 11th 2023

The addition of atezolizumab to bevacizumab, carboplatin, and pemetrexed or paclitaxel (ABCP) did not result in a statistically significant improvement in progression-free survival vs BCP for patients with metastatic nonsquamous non–small cell lung cancer in the first line, missing the primary end point of the phase 3 IMpower151 study.

Baseline Characteristics Not Tied to Benefit With Durvalumab/Tremelimumab and Chemo in Metastatic NSCLC

September 11th 2023

Treatment with durvalumab plus tremelimumab and chemotherapy led to higher rates of long-term clinical benefit compared with chemotherapy alone in the treatment of patients with first-line metastatic non–small cell lung cancer.

Perioperative Durvalumab Plus Chemo Yields Responses, EFS Benefit in Resectable NSCLC

September 11th 2023

The addition of perioperative durvalumab to neoadjuvant chemotherapy led to a significant improvement in terms of pathological complete response and event-free survival compared with placebo plus chemotherapy in patients with resectable non–small cell lung cancer.

Neoadjuvant Durvalumab Plus Chemo Followed by Adjuvant Durvalumab Does Not Provide Benefit for EGFR+ NSCLC

September 11th 2023

The addition of durvalumab to chemotherapy prior to surgery, followed by adjuvant durvalumab, did not provide a clear clinical benefit in patients with early-stage non–small cell lung cancer harboring an EGFR mutation, according to data from the phase 3 AEGEAN trial.

Zongertinib Proves Clinically Active With Low Rate of EGFR-Mediated AEs in HER2-Mutant Solid Tumors

September 11th 2023

Zongertinib will proceed to phase 1b evaluation at doses of 120 mg and 240 mg once daily in patients with HER2–mutant non–small cell lung cancer following preliminary efficacy signals and acceptable safety in patients with advanced HER2–mutant solid tumors enrolled in the dose-escalation portion of the phase 1a/b BEAMION Lung-1 trial.

Durvalumab Associated With Lower Real-World PFS in EGFR-Mutated NSCLC Vs EGFR Wild-Type NSCLC

September 11th 2023

Treatment with durvalumab was associated with lower real-world progression-free survival in patients with unresectable, stage III EGFR-mutated non–small cell lung cancer vs patients with EGFR wild-type disease.

FDA Approval Sought for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma

September 11th 2023

A rolling new drug application seeking the approval of tovorafenib monotherapy for the treatment of patients with relapsed or progressive pediatric low-grade glioma has been submitted to the FDA.

Frontline Osimertinib/Chemotherapy Combination Improves PFS in EGFR-Mutated NSCLC

September 11th 2023

Osimertinib in combination with platinum-based therapy and pemetrexed demonstrated a statistically significant and clinically meaningful improvement in progression-free survival vs osimertinib monotherapy in patients with EGFR-mutated advanced non–small cell lung cancer.

Fox Chase Cancer Center and Temple Health Welcome Dr. Randall A. Lee

September 11th 2023

Fox Chase Cancer Center and Temple Health are pleased to announce the hiring of Randall A. Lee, MD, as an Assistant Professor in the Department of Urology and a member of the Fox Chase-Temple Urologic Institute.

FDA Approves Motixafortide Plus Filgrastim for ASCT in Multiple Myeloma

September 11th 2023

The FDA has approved motixafortide (Aphexda) in combination with filgrastim (Neupogen) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous stem cell transplant in patients with multiple myeloma.